Lung cancer, Non small cell lung cancer (NSCLC)
Results
Phase 3
This trial looked at having the chemotherapy drug pemetrexed after combination chemotherapy for advanced non small cell lung cancer (NSCLC). The people taking part had types of NSCLC that are described as non squamous such as adenocarcinoma.
NSCLC is often diagnosed when it is quite advanced. Doctors may treat advanced NSCLC with chemotherapy, as well as giving treatment to control cancer symptoms (best supportive care).
Cisplatin is one of the chemotherapy drugs that doctors often use for NSCLC. You usually have it with another chemotherapy drug. This is called combination chemotherapy.
Researchers are trying to improve treatment for advanced NSCLC. In this trial, they looked at a drug called pemetrexed. The people who took part had a combination of pemetrexed and cisplatin. Some people then continued to have pemetrexed alone. Doctors call this maintenance therapy.
The aim of the trial was to see if maintenance pemetrexed and best supportive care were better than a dummy drug (placebo) and best supportive care after combination chemotherapy for advanced NSCLC.
Recruitment start: 15 January 2009
Recruitment end: 31 March 2010
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Mayukh Das
Eli Lilly and Company Limited
Last reviewed: 7 January 2014
CRUK internal database number: 1398
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
